Prevents itching associated with allergic conjunctivitis. Sold as Lastacaft. Every FDA application for this active ingredient: 1 branded and 3 generic.
As of Nov 14, 2026, FDA lists 4 applications for Alcaftadine (sold as Lastacaft), first approved Jul 28, 2010, with 1 new use approved and 0 published complete response letters.
| Jul 28, 2010 | LastacaftNDA 22134 ยท New molecular entity | Abbvie | 7 | Marketed |
| Jun 23, 2023 | AlcaftadineANDA 210659 | Eugia Pharma | 0 | Discontinued |
| Mar 1, 2024 | AlcaftadineANDA 209706 | Gland | 0 | Marketed |
| Oct 2, 2024 | AlcaftadineANDA 209290 | Alembic | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Abbvie
Eugia Pharma
Alembic